Minimal residual disease in malignant diseases of the blood I. Background and pre-clinical validation

Authors :: Peter Hokland
Charlotte Guldborg Nyvold
Jesper Stentoft
Hans Beier Ommen
Lene Hyldahl
Karin Braendstrup
Bodil Lind Andersen
Lone Siig
Mette Ostergaard
Source :: Hokland, P, Nyvold, C G, Stentoft, J, Ommen, H B, Hyldahl, L, Braendstrup, K, Andersen, B L, Siig, L & Ostergaard, M 2009, ' Minimal restsygdom ved maligne blodsygdomme I. Baggrund og praeklinisk validering ', Ugeskrift for Læger, bind 171, nr. 4, s. 229-31 ., Aarhus University
Publication Year :: 2009
Abstract: In haematological malignancies, molecular markers like fusion DNA from balanced translocations, point mutations, or over-expressed genes can now be used not only for diagnosis, but also for determination of the minimal residual disease (MRD) after cytoreduction with a sensitivity by far exceeding that of previous methodologies. The sensitivity of quantitative polymerase chain reaction typically reaches a validated identification of 1 malignant cell in 100,000. Udgivelsesdato: 2009-Jan-19

Subjects :: Leukemia
Neoplasm, Residual
Tumor Markers, Biological
Humans
Polymerase Chain Reaction
Sensitivity and Specificity

Language :: Danish
Database :: OpenAIRE
Journal :: Hokland, P, Nyvold, C G, Stentoft, J, Ommen, H B, Hyldahl, L, Braendstrup, K, Andersen, B L, Siig, L & Ostergaard, M 2009, ' Minimal restsygdom ved maligne blodsygdomme I. Baggrund og praeklinisk validering ', Ugeskrift for Læger, bind 171, nr. 4, s. 229-31 ., Aarhus University
Accession number :: edsair.dedup.wf.001..02ed4875f9150cdb47fff744afc110fd

Tools